Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma

Prostate

Volumn 53, Issue 2, 2002, Pages 118-123

  Fixemer, Thomas ^a   Remberger, Klaus ^a   Bonkhoff, Helmut ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Apoptosis; Immunohistochemistry; Neuroendocrine differentiation; Prostate cancer; TUNEL

Indexed keywords

CELL MARKER; CHROMOGRANIN A; DNA FRAGMENT;

APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; EXOCRINE CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; MALIGNANT TRANSFORMATION; NEUROSECRETORY CELL; NICK END LABELING; PHENOTYPE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; TUMOR CELL;

ADENOCARCINOMA; APOPTOSIS; CELL DIFFERENTIATION; CHROMOGRANIN A; CHROMOGRANINS; DNA FRAGMENTATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; NEOPLASM STAGING; NEUROSECRETORY SYSTEMS; PROSTATIC NEOPLASMS;

EID: 0036789162     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10133     Document Type: Article

References (28)

1. Di Sant' Agnese P. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic and therapeutic implications. Cancer 1992;70:254-268.
2. Di Sant' Agnese P. Neuroendocrine differentiation in prostatic carcinoma. Recent findings and new concepts. Cancer 1995;75: 1850-1859.
3. Di Sant' Agnese P, Cockett AT. Neuroendocrine differentiation in prostatic malignancy. Cancer 1996;78:357-361.
4. Cohen R, Glezerson O, Haffejee Z. Neuroendocrine cells: a new prognostic parameter in prostate cancer. Br J Urol 1991;68:258-262.
5. Weinstein MH, Partin AW, Veltri RW, Epstein JI. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progession after radical prostatectomy. Hum Pathol 1996;27: 683-687.
6. Grignon D, Caplan R, Sakr W, Porter A, Doggen RLS, John M, Abrams R, Lawton C. Neuroendocrine (NE) differentiation as a prognostic indicator in locally advanced prostate cancer (PCa). Lab Invest 1995;72:76A.
7. Bonkhoff H. Neuroendocrine cells in benign and malignant prostate tissue. Morphogenesis, proliferation and androgen receptor status. Prostate Suppl 1998;8:18-22.
8. Bonkhoff H, Stein U, Remberger K. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic and neoplastic human prostate. Virchows Arch A Pathol Anat 1993; 423:291-294.
9. Krijnen J, Janssen P, Ruizeveld de Winter JA, van Kimpen H, Schr6der F, van der Kwast T. Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry 1993;100:393-398.
10. Bonkhoff H, Wernert N, Dhom G, Remberger K. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic and neoplastic human prostate. Prostate 1991;18: 91-98.
11. Bonkhoff H, Stein U, Remberger K. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum Pathol 1995;26:167-170.
12. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schroder FH, van Steenbrugge GJ. Kinetics of neuroendocrine differentiation in an androgendependent human prostate xenograft model. Am J Pathol 1999; 154:543-551.
13. Stadelmann C, Lassmann H. Detection of apoptosis in tissue sections. Cell Tissue Res 2000;301:19-31.
14. Bardales RH, Xie SS, HSU SM. In situ DNA fragmentation assay for detection of apoptosis in paraffin-embedded tissue sections. Technical considerations. Am J Clin Pathol 1997;107:332-336.
15. Bonkhoff H, Fixemer T, Hunsicker I, Remberger K. Simultaneous detection of DNA fragmentation (apoptosis), cell proliferation (MIB-1), and phenotype markers in routinely processed tissue sections. Virchows Arch 1999;434:71-73.
16. Morris MJ, Scher HI. Novel strategies and therapeutics for the treatment of prostate carcinoma. Cancer 2000;89:1329-1348.
17. Isaacs JT. Apoptosis: translating theory to therapy for prostate cancer. J Natl Cancer Inst 2000;92:1367-1369.
18. Bruckheimer EM, Kyprianou N. Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target. Cell Tissue Res 2000;301:153-162.
19. Thompson TC, Yang G. Regulation of apoptosis in prostatic disease. Prostate Suppl 2000;9:25-28.
20. Aihara M, Truong LD, Dunn JK, Wheeler TM, Scardino PT, Thompson TC. Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol 1994; 25:797-801.
21. Stapleton AM, Zbell P, Kattan MW, Yang G, Wheeler TM, Scardino PT, Thompson TC. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer 1998;82:168-175.
22. Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D, Gospadarowicz M, Kaplan RS, Miller DS, Montironi R, Pajak TF, Pollack A, Srigley JR, Yarbro JW. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:995-1000.
23. Ruizeveld de Winter JA, Janssen PJA, Sleddens HM, VerleumMooijman MCT, Trapman J, Brinkmann AO, Samerse AB, Schroeder FH, Van der Kwast TH. Androgen receptor status in localized and locally progressive, hormone refractory human prostate cancer. Am J Pathol 1994;144:735-746.
24. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 1996;28:98-106.
25. Bonkhoff H, Stein U, Remberger K. Multidirectional differentiation in the normal, hyperplastic and neoplastic human prostate. Simultaneous demonstration of cell specific epithelial markers. Hum Pathol 1994;25:42-46.
26. Xue Y, Smedts F, Verhofstad A, Debruyne F, de la Rosette J, Schalken J. Cell kinetics of prostate exocrine and neuroendocrine epithelium and their prostate differential interrelationship: new perspectives. Prostate Suppl 1998;8: 62-73.
27. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
28. Berruti A, Dogliotti L, Mosca A, Bellina M, Mari M, Torta M, Tarabuzzi R, Bollito E, Fontana D, Angeli A. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000;88:2590-2597.